SLC5A2 and chronic kidney disease: The renoprotective effects of SGLT2 inhibitors were not expected when the first large controlled studies on cardiovascular safety emerged in the mid-2010s to test this new class of antidiabetic drugs.1 However, now they are considered a well-established and consolidated medication in controlling the progression of CKD in patients with or without diabetes.2 However, despite these excellent initial results at long term, concerns raised about the effect on a potential effect on AKI.